Comparative Study Between Ultrasound Guided Paravertebral Plane Block and Erector Spinae Plane Block on Post-operative Analgesia After Total Abdominal Hysterectomy

NCT07610070 | Not Yet Recruiting DMC

• 1 other identifier: FMASU MD354/2025
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The intent of this study is to compare the efficacy of the erector spinae plane block (ESPB) and paravertebral plane block in reducing postoperative opioid consumption and pain in patients with total abdominal hysterectomy.

Conditions

Post Operative Analgesia

Outcome Measures

Primary Outcomes (1)

• total morphine consumption

  Postoperative total morphine requirements in the first 24 hours after surgery.

  from the end of surgey to 24 hrs post operative

Study Arms (2)

Paravertebral Plane Block

ACTIVE COMPARATOR

the group will receive paravertebral plane block, The spinous process of the 10th thoracic vertebra will be located under the ultrasound guided (USG) linear probe. Under aseptic precautions, a 22-G short-beveled needle will be inserted under ultrasonographic guidance using the in-plane approach and was directed medially between the transverse process (TP) and the pleura. The needle will traverse the superior costotransverse ligament and enter the paravertebral space, where 2 ml of normal saline will be injected. The tip of the needle will be in the paravertebral space, noting the pleura being pushed down. Then, 20 ml of 0.25% bupivacaine will be injected into the paravertebral space under USG visualization.

Procedure: Paravertebral Plane Block; Drug: bupivicaine 0.25%

Erector Spinea Plane Block

ACTIVE COMPARATOR

the group will receive Erector Spinae Plane Block; The USG linear probe will be placed Longitudinal 3 cm lateral to T10 transverse process TP. A 22-G short-beveled needle will be inserted in the cephalad to caudal direction through the erector spinae to contact the T10 TP using the in-plane technique. After the needle made contact with TP, the plane will be confirmed by injecting 2ml of saline and depositing 20ml of 0.25% bupivacaine.

Procedure: Erector Spinea Plane Block; Drug: bupivicaine 0.25%

Interventions

Paravertebral Plane Block PROCEDURE

The spinous process of the 10th thoracic vertebra will be located under the ultrasound guided (USG) linear probe. Under aseptic precautions, a 22-G short-beveled needle will be inserted under ultrasonographic guidance using the in-plane approach and was directed medially between the transverse process (TP) and the pleura. The needle will traverse the superior costotransverse ligament and enter the paravertebral space, where 2 ml of normal saline will be injected. The tip of the needle will be in the paravertebral space, noting the pleura being pushed down. Then, 20 ml of 0.25% bupivacaine will be injected into the paravertebral space under USG visualization.

Paravertebral Plane Block

Erector Spinea Plane Block PROCEDURE

The USG linear probe will be placed Longitudinal 3 cm lateral to T10 transverse process TP. A 22-G short-beveled needle will be inserted in the cephalad to caudal direction through the erector spinae to contact the T10 TP using the in-plane technique. After the needle made contact with TP, the plane will be confirmed by injecting 2ml of saline and depositing 20ml of 0.25% bupivacaine.

Erector Spinea Plane Block

bupivicaine 0.25% DRUG

20 ml of 0.25% bupivacaine will be injected

Erector Spinea Plane Block; Paravertebral Plane Block

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• ASA I and ASA II patients.
• Female, 30-60 years of age.
• Scheduled for total abdominal hysterectomy.

You may not qualify if:

• Patient refusal of procedure or participation in the study.
• Opioid or analgesic abuse.
• Known allergy to study drug.
• Any contraindication of regional anesthesia including:
• Local infection at the site of puncture.
• Having history of hematological disorders, including coagulation abnormality.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams

Cairo, Abbasia, 00202, Egypt

Location

Central Study Contacts

Doaa Ramadan, MBBCH

CONTACT

01145211869; DoaaRamadan@med.asu.edu.eg

Doaa Ramadan, MBBCH

CONTACT

01145211869; doaaramdan2020@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2026
• First Posted: May 27, 2026
• Study Start: May 10, 2026
• Primary Completion (Estimated): January 15, 2027
• Study Completion (Estimated): April 20, 2027
• Last Updated: May 27, 2026

Record last verified: 2026-05

Locations

EG (1)